Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US12006555B2 · kind B2 · utility
0Cited by
9References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 21, 2020 |
| Grant date | Jun 11, 2024 |
| Priority date | — |
| Expiry date | Nov 2, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.